Notably, phase II‐III results of itepekimab, an anti‐IL‐33 monoclonal antibody, and dupilumab showed improvement in lung function in this particular COPD subset [101, 102]. The gene discussed is IL33; the disease is chronic obstructive pulmonary disease.